1056 related articles for article (PubMed ID: 26297071)
1. The progress in understanding and treatment of diabetic retinopathy.
Stitt AW; Curtis TM; Chen M; Medina RJ; McKay GJ; Jenkins A; Gardiner TA; Lyons TJ; Hammes HP; Simó R; Lois N
Prog Retin Eye Res; 2016 Mar; 51():156-86. PubMed ID: 26297071
[TBL] [Abstract][Full Text] [Related]
2. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
4. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
5. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
6. Influence of baseline diabetic retinopathy status on initial anatomical response of intravitreal ranibizumab therapy for diabetic macular oedema.
Nicholson L; Patrao NV; Ramu J; Vazquez-Alfageme C; Muwas M; Rajendram R; Hykin PG; Sivaprasad S
Eye (Lond); 2017 Sep; 31(9):1358-1364. PubMed ID: 28452992
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
[TBL] [Abstract][Full Text] [Related]
8. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.
Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG;
JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371
[TBL] [Abstract][Full Text] [Related]
9. Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.
Gross JG; Glassman AR; Klein MJ; Jampol LM; Ferris FL; Bressler NM; Beck RW
JAMA Ophthalmol; 2017 Jun; 135(6):672-673. PubMed ID: 28492921
[TBL] [Abstract][Full Text] [Related]
10. Vascular Endothelial Growth Factor and Diabetic Retinal Disease.
Ajlan RS; Silva PS; Sun JK
Semin Ophthalmol; 2016; 31(1-2):40-8. PubMed ID: 26959128
[TBL] [Abstract][Full Text] [Related]
11. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
12. A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.
Gross JG; Glassman AR
JAMA Ophthalmol; 2016 Jan; 134(1):13-4. PubMed ID: 26583372
[No Abstract] [Full Text] [Related]
13. Ranibizumab Plus Panretinal Photocoagulation versus Panretinal Photocoagulation Alone for High-Risk Proliferative Diabetic Retinopathy (PROTEUS Study).
Figueira J; Fletcher E; Massin P; Silva R; Bandello F; Midena E; Varano M; Sivaprasad S; Eleftheriadis H; Menon G; Amaro M; Ayello Scheer S; Creuzot-Garcher C; Nascimento J; Alves D; Nunes S; Lobo C; Cunha-Vaz J;
Ophthalmology; 2018 May; 125(5):691-700. PubMed ID: 29395119
[TBL] [Abstract][Full Text] [Related]
14. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of foveal capillary drop-out and previous panretinal photocoagulation for diabetic macular oedema treated with ranibizumab.
Ebneter A; Wolf S; Zinkernagel MS
Br J Ophthalmol; 2016 Mar; 100(3):365-70. PubMed ID: 26187951
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal ranibizumab alone or in combination with panretinal photocoagulation for the treatment of proliferative diabetic retinopathy with coexistent macular edema: long-term outcomes of a prospective study.
Chatziralli I; Dimitriou E; Theodossiadis G; Kazantzis D; Theodossiadis P
Acta Diabetol; 2020 Oct; 57(10):1219-1225. PubMed ID: 32472172
[TBL] [Abstract][Full Text] [Related]
17. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
18. Review of anti-VEGF therapy in proliferative diabetic retinopathy.
Jardeleza MS; Miller JW
Semin Ophthalmol; 2009; 24(2):87-92. PubMed ID: 19373692
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of ranibizumab combined with photocoagulation for diabetic retinopathy: A meta-analysis study.
Yin H; Zhong S
Medicine (Baltimore); 2023 Aug; 102(31):e34170. PubMed ID: 37543834
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
Payne JF; Wykoff CC; Clark WL; Bruce BB; Boyer DS; Brown DM;
Br J Ophthalmol; 2021 Feb; 105(2):253-257. PubMed ID: 32303499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]